BioCryst Pharmaceuticals, Inc. Financials

Market Capitalization $1.60 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-6.47
Forward PE	-193.25
Price to Sales TTM	$3.88
Price to Book MRQ	$-3.37
Enterprise to Revenue	5.12
Enterprise to EBITDA	-66.16

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-30.01%
Operating Margin	6.57%
Return on Assets TTM	-4.25%
Return on Equity TTM	49.73%

Income Statement

Revenue TTM	$412,579,008
Revenue per Share TTM	$2.01
Quarterly Revenue Growth	35.00%
Gross Profit TTM	$215,114,000
EBITDA	$-31,941,000
Net Income to Common TTM	$-123,817,000
Diluted EPS TTM	$-0.61
Quarterly Earnings Growth YoY	34.98%

Balance Sheet

Total Cash MRQ	$330,012,992
Total Cash per Share MRQ	$1.59
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.80
Current Ratio MRQ	2.78
Book Value per Share MRQ	$-2.26

Cash Flow

Operating Cash Flow TTM	$-55,725,000
Levered Free Cash Flow TTM	$15,866,125

BCRX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	207,132,992
Float Shares	192,654,004
Avg 10 Volume	2,876,990
Avg 30 Volume	None
Shares Short	15,721,517
Short Ratio	8.60
Short % of Shares	7.65%
% Held by Insiders	1.46%
% Held by Institutions	84.58%

Stock Price Summary

Beta	1.89
Fifty Two Week Low	$4.03
Fifty Two Week High	$8.88
Fifty Two Week Change	25.79%
Day 50 MA	$7.57
Day 200 MA	$7.02

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2014-06-11
Last Split Factor
Last Split Date